Molecular Cytogenetics Market by Product (Kit, Reagent, Probe, Consumable, Software, Service), Technique (In-Situ, FISH, Comparative Genomic Hybridization), Application (Cancer, Genetic), End User (Research Labs, Institutes) - Forecast to 2021
[147 Pages Report] The molecular cytogenetics market is projected to reach USD 2.52 Billion by 2021 from USD 1.55 Billion in 2016, at a CAGR of 10.1% from 2016 to 2021. The high incidence and large economic burden of genetic disorders and cancer and rise in healthcare expenditure has resulted in the increasing use of molecular cytogenetic products in clinical and research laboratories, academic research institutes, and pharmaceutical and biotechnology companies. The base year considered for the study is 2015, and the forecast has been provided for the period between 2016 and 2021.
Market Dynamics
Drivers
- Increasing Incidence of Genetic Disorders and Cancer
- Growing Focus on Targeted Cancer Treatment
- Increasing Aging Population and Subsequent Rise in Prevalence of Chronic Diseases
- Increasing Penetration of Molecular Cytogenetics in Clinical Pathological Testing
Restraint
- High Cost of Advanced Instruments
- Unfavourable Reimbursement Scenario
Opportunities
- Untapped Emerging Markets in Asia
Trends
- Transition From Fish to Array-Based Techniques
The objectives of this study are as follows:
- To define, describe, and forecast the global molecular cytogenetics market by product, technique, application, end user, and region
- To provide detailed information regarding the major factors influencing market growth (drivers, restraints, and opportunities)
- To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall molecular cytogenetics market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to four main regions, namely, North America, Europe, Asia, and the Rest of the World (RoW)
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze competitive developments such as product launches, agreements, expansions, acquisitions, and other developments in the global molecular cytogenetics market
Research Methodology
Top-down and bottom-up approaches were used to estimate and validate the size of the global molecular cytogenetics market and to estimate the size of various other dependent submarkets. The overall market size was used in the top-down approach to estimate the sizes of other individual markets (mentioned in the market segmentation—by products and region) through percentage splits from secondary and primary research. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained.
Various secondary sources referred to for this research study include publications from government sources such as the white papers; articles from recognized authors; gold standard and silver standard websites, directories, and databases; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations have been used to identify and collect information useful for this extensive commercial study of the molecular cytogenetics market. Primary sources such as experts from related industries and suppliers have been interviewed to obtain and verify critical information as well as to assess prospects of the molecular cytogenetics market. The breakdown of profiles of primaries is shown in the figure below:
To know about the assumptions considered for the study, download the pdf brochure
The major players in the molecular cytogenetics market are F. Hoffmann-La Roche Ltd. (Switzerland) Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Abbott Laboratories (US), Agilent Technologies (US), PerkinElmer, Inc. (US), Illumina, Inc. (US), Bio-Rad Laboratories (US), Oxford Gene Technology (UK), and Applied Spectral Imaging (US).
Target Audience for this Report:
- Manufacturers and Suppliers of Molecular Cytogenetics Instruments and Consumables
- Clinical and Research Laboratories
- Pharmaceutical and Biotechnology Companies
- Academic Research Institutes related to Molecular Cytogenetics Market
- Venture Capitalists and Investors
Value Addition for the Buyer:
This report provides insights into the global molecular cytogenetics market. It provides valuable information on the products, applications, and regions in the molecular cytogenetics market. The geographic analysis for these segments is also presented in this report. Leading players in the market are profiled to study their device offerings and understand strategies undertaken by them to be competitive in this market.
The above-mentioned information would help the buyer understand market dynamics. In addition, the forecasts provided in the report will enable firms to understand the trends in this market and better position themselves to capitalize on the growth opportunities.
Major Market Developments
- In January 2014, Roche acquired Genia Technologies, Inc. (U.S.). This acquisition strengthened Roche's Next Generation Sequencing pipeline.
- In February 2015, Roche acquired Signature Diagnostics AG (Germany).
- In January 2016, Thermo Fisher Scientific, Inc. acquired Affymetrix (U.S.). This acquisition strengthened Thermo Fisher Scientific's leadership into bioscience business and create new market opportunities in genetic analysis.
- In July 2016, Thermo Fisher Scientific and HEALTH BioMed (China) collaborated to support HBM’s development of molecular diagnostic kits for infectious diseases and pharmacogenomics screening which will serve the Chinese market.
Critical questions the report answers
- How the market developments of key players impact the overall industry?
- What are the restraining factors for the molecular cytogenetics market?
Targeted therapies differ from standard chemotherapy in several ways. These therapies act on specific molecular targets associated with cancer, whereas most standard chemotherapies act on all rapidly dividing normal and cancerous cells. In solid tumors, significantly high levels of chromosome abnormalities have been detected, but distinction between critical and irrelevant events has been a major challenge. The emergence of molecular-based cytogenetic techniques such as fluorescence in situ hybridization is particularly useful for solid malignancies, and the spectrum of their application is rapidly expanding to improve efficiency and sensitivity in cancer prevention, diagnosis, prognosis, and therapy selection, alone or in combination with other diagnostic methods. The increasing use for molecular cytogenetics in clinical oncology will drive the growth of the global molecular cytogenetics market.
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
Request Sample Scope of the Report
:
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
This report categorizes the molecular cytogenetics market into the following segments:
Molecular Cytogenetics Market, By Product
-
Kits & Reagents
- Testing Kits
- Probes
- Fluorescent Affinity Reagents
- Other Kits & Reagents
- Instruments
- Consumables
- Software & Services
Molecular Cytogenetics Market, By Technique
-
Comparative Genomic Hybridization
- Array-Based Comparative Genomic Hybridization
- Standard Comparative Genomic Hybridization
- Fluorescence in Situ Hybridization
- In Situ Hybridization
- Other Techniques
Molecular Cytogenetics Market, By Application
- Genetic Disorders
- Cancer
- Personalized Medicine
- Other Applications
Molecular Cytogenetics Market, By End User
- Clinical & Research Laboratories
- Academic Research Institutes
- Pharmaceutical and Biotechnology Companies
- Other End Users
Molecular Cytogenetics Market, by Region
-
North America
- US
- Canada
- Europe
-
Asia
- China
- Japan
- India
- RoA
- Rest of the World (RoW)
Customization Options:
- Company Information: Detailed company profiles of five or more market players
- Opportunities Assessment: A detailed report underlining the various growth opportunities presented in the market.
The molecular cytogenetics market is projected to reach USD 2.52 Billion by 2021 from USD 1.55 Billion in 2016, at a CAGR of 10.1% from 2016 to 2021. The high incidence and large economic burden of genetic disorders and cancer and rise in healthcare expenditure has resulted in the increasing use of molecular cytogenetic products in clinical and research laboratories, academic research institutes, and pharmaceutical and biotechnology companies.
The molecular cytogenetics market is segmented based on products, techniques, application, end user, and region. On the basis of product, the market is segmented into kits and reagents, instruments, consumables, and software and services. The kits and reagents segment is expected to account for the largest share of the global market in 2016; the increasing incidence of genetic disorders and cancer is a key market driver in this segment.
On the basis of technique, the market is segmented into comparative genomic hybridization (CGH), fluorescence in situ hybridization (FISH), in situ hybridization (ISH), and other techniques. CGH forms the largest and fastest-growing technology segment of this market, as the increasing laboratory automation will increase areas of application of CGH in molecular cytogenetics market.
Based on application, the molecular cytogenetics market is segmented into genetic disorders, cancer, personalized medicine, and other applications. The genetic disorders segment accounts for the largest share of the global market in 2016; and on the basis of end users, the market is segmented into clinical and research laboratories, academic research institutes, pharmaceutical and biotechnology companies, and others. The clinical and research laboratories segment is expected to account for the largest share of the global market in 2016.
The global molecular cytogenetics market is segmented into four major regions North America, Europe, Asia, and Rest of the World. Geographically, the global market is dominated by North America. Growth in the North American segment is primarily driven by the high incidence of genetic disorders and cancer, rapid growth in the aging population, and high healthcare expenditure.
High Cost of Advanced Instruments Will Restrain the Growth of this Market
The implementation of molecular cytogenetics in clinical & research laboratories requires high capital investments. The instruments needed for cytogenetics research and procedures are expensive since they are equipped with advanced features and functionalities. Owing to their high costs, companies and research institutes with smaller R&D budgets cannot afford to purchase or produce such expensive instruments.
On the other hand, pharmaceutical companies will require many such systems to maintain efficiency, and hence their capital cost increases significantly. Furthermore, academic research laboratories find it difficult to invest in such systems as they have controlled budgets. In developing countries owing to budget constraints, small- and medium-sized hospitals and clinical pathology laboratories cannot afford high priced, fully automated, technologically advanced instruments.
Another major barrier is the complexity of manufacturing cytogenetics kits & reagents, probes, and instruments. The development process for cytogenetics products is highly complex and costly that requires significant investments, technical capabilities, clinical trial expertise, scientific standards, and quality systems. End users who do not require regular molecular cytogenetics testing and have low budgets are therefore reluctant towards the implementation of advanced systems. This is restraining the growth of this market.
Key players in the molecular cytogenetics market include F. Hoffmann-La Roche Ltd. (Switzerland) Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Abbott Laboratories (US), Agilent Technologies (US), PerkinElmer, Inc. (US), Illumina, Inc. (US), Bio-Rad Laboratories (US), Oxford Gene Technology (UK), and Applied Spectral Imaging (US).
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
Table of Contents
1 Introduction (Page No. - 13)
1.1 Objectives of the Study
1.2 Molecular Cytogenetics Market Definition
1.3 Markets Covered
1.3.1 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders
2 Research Methodology (Page No. - 16)
2.1 Secondary Data
2.1.1 Key Data From Secondary Sources
2.2 Primary Data
2.2.1 Key Data From Primary Sources
2.3 Molecular Cytogenetics Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Market Breakdown and Data Triangulation
2.5 Assumptions for the Study
3 Executive Summary (Page No. - 24)
3.1 Conclusion
4 Premium Insights (Page No. - 30)
4.1 Molecular Cytogenetics: Market Overview
4.2 Geographic Analysis: Market, By Techniques
4.3 Molecular Cytogenetics Market Size, By Application
5 Market Overview (Page No. - 34)
5.1 Introduction
5.2 Molecular Cytogenetics Market Dynamics
5.2.1 Market Drivers
5.2.1.1 Increasing Incidence of Genetic Disorders and Cancer
5.2.1.2 Growing Focus on Targeted Cancer Treatment
5.2.1.3 Increasing Aging Population and Subsequent Rise in Prevalence of Chronic Diseases
5.2.1.4 Increasing Penetration of Molecular Cytogenetics in Clinical Pathological Testing
5.2.2 Market Restraints
5.2.2.1 High Cost of Advanced Instruments
5.2.2.2 Unfavourable Reimbursement Scenario
5.2.3 Market Opportunities
5.2.3.1 Untapped Emerging Markets in Asia
5.2.4 Market Trends
5.2.4.1 Transition From Fish to Array-Based Techniques
6 Molecular Cytogenetics Market, By Product (Page No. - 41)
6.1 Introduction
6.2 Kits & Reagents
6.2.1 Testing Kits
6.2.2 Probes
6.2.3 Fluorescent Affinity Reagents
6.2.4 Other Kits & Reagents
6.3 Instruments
6.4 Consumables
6.5 Software & Services
7 Molecular Cytogenetics Market, By Technique (Page No. - 51)
7.1 Introduction
7.2 Comparative Genomic Hybridization
7.2.1 Array-Based Comparative Genomic Hybridization
7.2.2 Standard Comparative Genomic Hybridization
7.3 Fluorescence in Situ Hybridization
7.4 In Situ Hybridization
7.5 Other Techniques
8 Molecular Cytogenetics Market, By Application (Page No. - 60)
8.1 Introduction
8.2 Genetic Disorders
8.3 Cancer
8.4 Personalized Medicine
8.5 Other Applications
9 Molecular Cytogenetics Market, By End User (Page No. - 66)
9.1 Introduction
9.2 Clinical & Research Laboratories
9.3 Academic Research Institutes
9.4 Pharmaceutical and Biotechnology Companies
9.5 Other End Users
10 Molecular Cytogenetics Market, By Region (Page No. - 72)
10.1 Introduction
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.4 Asia
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 RoA
10.5 Rest of the World (RoW)
11 Competitive Landscape (Page No. - 109)
11.1 Introduction
11.2 Strategic Overview
11.3 Molecular Cytogenetics Market Share Analysis
11.4 Competitive Situation and Trends
11.4.1 Collaborations, Agreements, and Partnerships
11.4.2 New Product Launches
11.4.3 Acquisitions
11.4.4 Expansions
11.4.5 Other Developments
12 Company Profiles (Page No. - 116)
(Company at A Glance, Recent Financials, Products & Services, Strategies & Insights, & Recent Developments)*
12.1 Introduction
12.2 ABBott Laboratories, Inc.
12.3 Agilent Technologies, Inc.
12.4 Applied Spectral Imaging
12.5 Bio-Rad Laboratories, Inc.
12.6 Danaher Corporation
12.7 Illumina, Inc.
12.8 Oxford Gene Technology (OGT)
12.9 Perkinelmer, Inc.
12.10 F. Hoffmann-LA Roche Ltd.
12.11 Thermo Fisher Scientific Inc.
*Details on Company at A Glance, Recent Financials, Products & Services, Strategies & Insights, & Recent Developments Might Not Be Captured in Case of Unlisted Companies.
13 Appendix (Page No. - 138)
13.1 Insights of Industry Experts
13.2 Discussion Guide
13.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
13.4 Introducing RT: Real-Time Market Intelligence
13.5 Available Customizations
13.6 Related Reports
13.7 Author Details
List of Tables (78 Tables)
Table 1 Prevalence of Genetic Disorders (2012)
Table 2 Incidence of Cancer, By Country (2012)
Table 3 Molecular Cytogenetics Market Size, By Product, 2014–2021 (USD Million)
Table 4 Molecular Cytogenetics Kits and Reagents Market Size, By Type, 2014–2021 (USD Million)
Table 5 Molecular Cytogenetics Kits and Reagents Market Size, By Region, 2014–2021 (USD Million)
Table 6 Market Size for Testing Kits, By Region, 2014–2021 (USD Million)
Table 7 Market Size for Probes, By Region, 2014–2021 (USD Million)
Table 8 Market Size for Fluorescent Affinity Reagents, By Region, 2014–2021 (USD Million)
Table 9 Market Size for Other Kits and Reagents, By Region, 2014–2021 (USD Million)
Table 10 Molecular Cytogenetics Instruments Market Size, By Region, 2014–2021 (USD Million)
Table 11 Molecular Cytogenetics Consumables Market Size, By Region, 2014–2021 (USD Million)
Table 12 Molecular Cytogenetics Software and Services Market Size, By Region, 2014–2021 (USD Million)
Table 13 Market Size, By Technique, 2014–2021 (USD Million)
Table 14 Comparative Genomic Hybridization Market Size, By Region, 2014–2021 (USD Million)
Table 15 Comparative Genomic Hybridization Market Size, By Type, 2014–2021 (USD Million)
Table 16 Array-Based Comparative Genomic Hybridization Market Size, By Region, 2014–2021 (USD Million)
Table 17 Standard Comparative Genomic Hybridization Market Size, By Region, 2014–2021 (USD Million)
Table 18 Fluorescence in Situ Hybridization Market Size, By Region, 2014–2021 (USD Million)
Table 19 in Situ Hybridization Market Size, By Region, 2014–2021 (USD Million)
Table 20 Other Molecular Cytogenetics Techniques Market Size, By Region, 2014–2021 (USD Million)
Table 21 Market Size, By Application, 2014–2021 (USD Million)
Table 22 Global Market Size for Genetic Disorders, By Region, 2014–2021 (USD Million)
Table 23 Market Size for Cancer, By Region, 2014–2021 (USD Million)
Table 24 Market Size for Personalized Medicine, By Region, 2014–2021 (USD Million)
Table 25 Other Molecular Cytogenetics Applications Market Size, By Region, 2014–2021 (USD Million)
Table 26 Market Size for Clinical and Research Laboratories, By Region, 2014–2021 (USD Million)
Table 27 Market Size for Pharmaceutical and Biotechnology Companies, By Region, 2014–2021 (USD Million)
Table 28 Market Size for Other End Users, By Region, 2014–2021 (USD Million)
Table 29 Market Size, By Region, 2014–2021 (USD Million)
Table 30 List of Related Conferences Held in North America
Table 31 North America: Market Size, By Country, 2014–2021 (USD Million)
Table 32 North America: Market Size, By Product, 2014–2021 (USD Million)
Table 33 North America: Market Size, By Technique, 2014–2021 (USD Million)
Table 34 North America: Market Size, By Application, 2014–2021 (USD Million)
Table 35 North America: Market Size, By End User, 2014–2021 (USD Million)
Table 36 U.S.: Market Size, By Product, 2014–2021 (USD Million)
Table 37 U.S.: Market Size, By Technique, 2014–2021 (USD Million)
Table 38 U.S.: Market Size, By Application, 2014–2021 (USD Million)
Table 39 U.S.: Market Size, By End User, 2014–2021 (USD Million)
Table 40 Canada: Market Size, By Product, 2014–2021 (USD Million)
Table 41 Canada: Market Size, By Technique, 2014–2021 (USD Million)
Table 42 Canada: Market Size, By Application, 2014–2021 (USD Million)
Table 43 Canada: Market Size, By End User, 2014–2021 (USD Million)
Table 44 Europe: Market Size, By Product, 2014–2021 (USD Million)
Table 45 Europe: Market Size, By Technique, 2014–2021 (USD Million)
Table 46 Europe: Market Size, By Application, 2014–2021 (USD Million)
Table 47 Europe: Market Size, By End User, 2014–2021 (USD Million)
Table 48 Asia: Market Size, By Country, 2014–2021 (USD Million)
Table 49 Asia: Market Size, By Product, 2014–2021 (USD Million)
Table 50 Asia: Market Size, By Technique, 2014–2021 (USD Million)
Table 51 Asia: Market Size, By Application, 2014–2021 (USD Million)
Table 52 Asia: Market Size, By End User, 2014–2021 (USD Million)
Table 53 China: Market Size, By Product, 2014–2021 (USD Million)
Table 54 China: Market Size, By Technique, 2014–2021 (USD Million)
Table 55 China: Market Size, By Application, 2014–2021 (USD Million)
Table 56 China: Market Size, By End User, 2014–2021 (USD Million)
Table 57 Japan: Market Size, By Product, 2014–2021 (USD Million)
Table 58 Japan: Market Size, By Technique, 2014–2021 (USD Million)
Table 59 Japan: Market Size, By Application, 2014–2021 (USD Million)
Table 60 Japan: Market Size, By End User, 2014–2021 (USD Million)
Table 61 India: Market Size, By Product, 2014–2021 (USD Million)
Table 62 India: Market Size, By Technique, 2014–2021 (USD Million)
Table 63 India: Market Size, By Application, 2014–2021 (USD Million)
Table 64 India: Market Size, By End User, 2014–2021 (USD Million)
Table 65 RoA: Market Size, By Product, 2014–2021 (USD Million)
Table 66 RoA: Market Size, By Technique, 2014–2021 (USD Million)
Table 67 RoA: Market Size, By Application, 2014–2021 (USD Million)
Table 68 RoA: Market Size, By End User, 2014–2021 (USD Million)
Table 69 RoW: Market Size, By Product, 2014–2021 (USD Million)
Table 70 RoW: Market Size, By Technique, 2014–2021 (USD Million)
Table 71 RoW: Market Size, By Application, 2014–2021 (USD Million)
Table 72 RoW: Market Size, By End User, 2014–2021 (USD Million)
Table 73 Growth Strategy Matrix, (2014–2016)
Table 74 Collaborations, Agreements, and Partnerships (2014–2016)
Table 75 New Product Launches (2014–2016)
Table 76 Acquisitions (2014–2016)
Table 77 Expansions (2014–2016)
Table 78 Other Developments (2014–2016)
List of Figures (47 Figures)
Figure 1 Global Molecular Cytogenetics Market
Figure 2 Research Design
Figure 3 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 4 Molecular Cytogenetics Market : Bottom-Up Approach
Figure 5 Market: Top-Down Approach
Figure 6 Data Triangulation Methodology
Figure 7 Global Molecular Cytogenetics Market Size, By Product, 2016 vs 2021 (USD Million)
Figure 8 Global Market Size, By Technique, 2016 vs 2021 (USD Million)
Figure 9 Global Market Size, By Application, 2016 vs 2021 (USD Million)
Figure 10 Global Market Size, By End User, 2016 vs 2021 (USD Million)
Figure 11 Geographic Snapshot of the Global Market
Figure 12 Global Market to Witness Double-Digit Growth During the Forecast Period
Figure 13 Comparative Genomic Hybridization Segment to Dominate the Global Market in 2016
Figure 14 Genetic Disorders Segment Will Continue to Dominate the Market in 2021
Figure 15 Asia to Register the Highest CAGR During the Forecast Period
Figure 16 Molecular Cytogenetics Market: Drivers, Restraints, Opportunities, and Trends
Figure 17 Market Segmentation, By Product
Figure 18 Kits and Reagents Will Continue to Dominate the Molecular Cytogenetics Products Market During the Forecast Period
Figure 19 Comparative Genomic Hybridization to Dominate the Market During the Forecast Period
Figure 20 Array-Based CGH Will Continue to Dominate the CGH Market During the Forecast Period
Figure 21 Genetic Disorders Applications Segment to Dominate the Market During the Forecast Period
Figure 22 Clinical and Research Laboratories to Dominate the Molecular Cytogenetics End-User Market During the Forecast Period
Figure 23 Molecular Cytogenetics Market , By Region (Market Size and Growth Rate), 2016
Figure 24 Market in Europe to Grow at the Highest Rate During the Forecast Period
Figure 25 North America: Market Snapshot
Figure 26 U.S. to Dominate the North American Market in 2016
Figure 27 Kits and Reagents, the Largest Product Segment in the North American Market in 2016
Figure 28 Kits & Reagents are Estimated to Be the Largest Product Segment in the European Market in 2016
Figure 29 Asia: Market Snapshot
Figure 30 China is Estimated to Dominate the Asian Market in 2016
Figure 31 Kits and Reagents to Grow at the Highest CAGR of the Asian Market, By Product, in 2016
Figure 32 Kits and Reagents to Hold A Major Share of the Chinese Market, By Product, in 2016
Figure 33 Kits and Reagents to Hold A Major Share of the Japanese Market, By Product, in 2016
Figure 34 Kits and Reagents to Hold A Major Share of the Indian Market, By Product, in 2016
Figure 35 Kits and Reagents to Hold A Major Share of the RoA Market, By Product, in 2016
Figure 36 Kits and Reagents Segment to Grow at the Highest CAGR in the RoW Market
Figure 37 Collaborations, Agreements and Partnerships Were the Key Strategies Adopted By Players in the Molecular Cytogenetics Market
Figure 38 Molecular Cytogenetics Market Share Analysis, By Key Player, 2015
Figure 39 Geographic Revenue Mix of the Top Market Players
Figure 40 Company Snapshot: ABBott Laboratories, Inc.
Figure 41 Company Snapshot: Agilent Technologies, Inc.
Figure 42 Company Snapshot: Bio-Rad Laboratories, Inc.
Figure 43 Company Snapshot: Danher Corporation
Figure 44 Company Snapshot: Illumina, Inc.
Figure 45 Company Snapshot: Perkinelmer, Inc.
Figure 46 Company Snapshot: F. Hoffmann-LA Roche Ltd.
Figure 47 Company Snapshot: Thermo Fisher Scientific Inc.
Generating Response ...
Growth opportunities and latent adjacency in Molecular Cytogenetics Market